hepatitis b vaccine FAQ

When did hepatitis B vaccine become available?
The first hepatitis B vaccine became commercially available in the United States in 1982. In 1986, a hepatitis B vaccine produced by recombinant DNA technology was licensed, and a second recombinant-type hepatitis B vaccine was licensed in 1989.

What are the names of the hepatitis B vaccines available in the United States?
The two recombinant vaccines (Recombivax HB® and Engerix-B®) are the only hepatitis B vaccine preparations currently used in the United States. (There are additional products licensed in the U.S. that contain these vaccines in combination with other vaccines.)

What kind of vaccines are they?
The hepatitis B vaccines used in the United States are recombinant DNA vaccines, which means they are produced by inserting the gene for HBV into common baker’s yeast where it is grown, harvested, and purified. HBV infection cannot occur from receiving hepatitis B vaccine.

How is this vaccine given?
Hepatitis B vaccine should be given to infants (12 months of age and younger) in the thigh muscle. Either the thigh or the upper arm muscle may be used for young children. The upper arm muscle is the preferred site of administration for adolescents and adults. Hepatitis B vaccine should always be given into the muscle despite the age of the patient.

Who should get this vaccine?
Hepatitis B vaccine, usually a three-dose series, is recommended for all children 0-18 years of age. It is recommended for infants beginning at birth in the hospital. All older children who did not get all the recommended doses of hepatitis B vaccine as an infant should complete their vaccine series as soon as possible. Most states require hepatitis B vaccine for school entry. Adolescents who are just starting their series will need two or three doses, depending on their age and the brand of vaccine used. Adults at increased risk of acquiring HBV infection should also be vaccinated. In addition, the vaccine can be given to any person who desires protection from hepatitis B.

What groups of adults are at increased risk of HBV infection?

* Healthcare workers and public safety workers with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids
* Men who have sex with men
* Sexually active people who are not in long-term, mutually monogamous relationships
* People seeking evaluation or treatment for a sexually transmitted disease
* Current or recent injection drug users
* Inmates of long-term correctional facilities
* People with end-stage kidney disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients
* Staff and residents of institutions or group homes for the developmentally challenged
* Household members and sex partners of people with chronic HBV infection
* Susceptible (non-infected) people from United States populations known to previously or currently have high rates of childhood HBV infection, including Alaska Natives, Pacific Islanders, and immigrants or refugees from countries with intermediate or high rates of chronic HBV infection. To see a list of these countries, go to http://www.cdc.gov/ncidod/diseases/hepatitis/b/country_listing.htm
* International travelers to regions with high or intermediate rates of HBV infection. To see a list of these countries, go to http://www.cdc.gov/ncidod/diseases/hepatitis/b/country_listing.htm

In addition, any adult who wishes to be protected from HBV infection should be vaccinated without having to acknowledge a specific risk factor.

If you have not been fully vaccinated with hepatitis B vaccine and you are cared for in any of the following settings, you should ask the setting’s healthcare provider to fully vaccinate you with hepatitis B vaccine. These setting include:

* Sexually transmitted disease treatment facilities
* HIV testing and treatment facilities
* Facilities providing drug-abuse treatment and prevention services
* Healthcare settings targeting services to injection drug users
* Correctional facilities
* Healthcare settings targeting services to men who have sex with men
* Chronic-hemodialysis facilities and end-stage renal disease programs
* Institutions and nonresidential day care facilities for developmentally challenged people

Who recommends this vaccine?
The Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Physicians (ACP), and American College of Obstetricians and Gynecologists (ACOG) recommend this vaccine.

Is hepatitis B vaccine safe?
Yes. Hepatitis B vaccines have been demonstrated to be safe when administered to infants, children, adolescents, and adults. Since 1982, more than an estimated 70 million adolescents and adults and more than 50 million infants and children have received at least one dose of hepatitis B vaccine in the United States. The majority of children who receive this vaccine have no side effects. Serious reactions are rare.

What side effects have been reported with this vaccine?
Of those children experiencing a side effect, most will have only a very mild reaction, such as soreness at the injection site (fewer than one out of three children) or low-grade fever. Adults are slightly more likely to experience such mild symptoms. Serious allergic reactions following hepatitis B vaccination are rare.

How effective is this vaccine?
After three properly administered doses of vaccine, at least 9 out of 10 healthy young adults and more than 9 out of 10 infants, children, and adolescents develop protective antibodies and subsequent immunity to HBV infection.

Why is this vaccine recommended for all babies when most of them won’t be exposed to HBV for many years, if then?
There are three basic reasons for recommending that all infants receive hepatitis B vaccine, starting at birth.

First, babies and young children have a very high risk for developing chronic HBV infection if they become infected at a young age.

It is estimated that about 1 out of 3 of the nearly 1 million Americans with chronic HBV infection acquired their infection as infants or young children. Those with chronic HBV infection are most likely to spread the infection to others. Infants and children who become chronically infected have an increased risk of dying prematurely from liver cancer or cirrhosis.

In contrast to other vaccine-preventable diseases of childhood, HBV infection in infants and young children usually produces no symptoms. Thus, the small number of reported cases of hepatitis B among children represents the tip of the iceberg of all HBV infections in children. For every child with symptoms of hepatitis B, there are at least 100 HBV-infected children with no symptoms—hence the increased risk to spread the infection to others without knowing it.

Second, early childhood infection occurs. About 16,000 children under 10 years of age were infected with HBV every year in the United States before routine infant hepatitis B vaccination was recommended. Although these infections represented few of all HBV infections in the United States, it is estimated that 18 out of 100 people with chronic HBV infection in the United States acquired their infection during early childhood. Clearly, infections occur among unvaccinated infants born to mothers who are not HBV-infected. In addition, unvaccinated foreign-born children account for a high proportion of infections. More effort needs to be placed on vaccinating these unprotected children.

Most early childhood spread of HBV occurs in households where a person has chronic HBV infection, but the spread of HBV has also been recognized in daycare centers and schools. The most probable ways children become infected with HBV are from skin puncture (e.g., biting) or from having their mucous membranes or cuts and scratches come in contact with infectious body fluids from an HBV-infected person. HBV remains infectious for at least seven days outside the body and can be found on and spread through sharing of inanimate objects such as washcloths or toothbrushes.

Third, long-term protection following infant vaccination is expected to last for decades and will ultimately protect against acquiring infection at any age.

Why should your child be protected against hepatitis B if h/she won’t ever inject drugs or be sexually promiscuous?
HBV can be transmitted in many ways in addition to sex contact and injection drug use. On average, an unvaccinated baby born in the United States has 5 out of 100 chances of developing HBV infection sometime during his or her lifetime. By avoiding obvious means of exposure, people can reduce their odds of becoming infected. But while there are degrees of risk involved in contracting HBV infection, there is no such thing as “no risk.” Moreover, hepatitis B vaccine is the first vaccine to prevent cancer–HBV-related liver cancer.

Tags: Hepatitis B